Next 10 |
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...
2024-04-07 01:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-05 15:00:12 ET More on the markets SPY: The Correction May Be Massive S&P 500: International Risk Assessment My Current View Of The Market: April 2024 Edition (Technical Analysis) S&P 500 holds its bullish trend as it defends the 20-day MA yet...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferati...
2024-03-27 16:50:31 ET Gainers: Athira Pharma ( ATHA ) +5% . ContextLogic ( WISH ) +5% . Angi ( ANGI ) +4% . Xeris Biopharma Holdings ( XERS ) +4% . Inozyme Pharma ( INZY ) +3% . Losers: MillerKnoll ( ...
- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare dis...
2024-03-18 02:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-12 09:46:49 ET More on Inozyme Pharma Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma ...
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT062...
News, Short Squeeze, Breakout and More Instantly...
Inozyme Pharma Inc. Company Name:
INZY Stock Symbol:
NASDAQ Market:
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...